Abbvie INC

AbbVie Inc. announced robust second-quarter 2026 financial results, with net revenues up 10.2% and adjusted diluted EPS increasing 22.9%, alongside a definitive agreement to acquire Apogee Therapeutics for approximately $10.9 billion.

AbbVie Inc. announced updated 2026 financial guidance, incorporating $291 million in acquired IPR&D and milestones expense for the second quarter, impacting diluted EPS by $0.17.

AbbVie Inc. reported the results of its 2026 Annual Meeting of Stockholders, detailing votes on director elections, auditor ratification, executive compensation, and charter amendments.

AbbVie Inc. announced first-quarter 2026 financial results, exceeding expectations with a 12.4% increase in net revenues and raising its full-year adjusted diluted EPS guidance.

AbbVie Inc. reported preliminary Q1 2026 results, noting $744 million in acquired IPR&D and milestones expense, impacting EPS by $0.41 and adjusting full-year guidance.

AbbVie Inc. successfully completed an underwritten public offering of $8 billion in senior notes across multiple tranches with varying maturities and interest rates.

AbbVie Inc. announced robust second-quarter 2026 financial results, driven by strong performance in immunology and neuroscience, alongside a significant acquisition of Apogee Therapeutics.

AbbVie reports Q1 2026 net revenues of $15.0 billion, driven by strong growth in Skyrizi and Rinvoq, despite ongoing Humira biosimilar competition.

AbbVie reports robust third-quarter 2025 revenue growth driven by immunology and neuroscience, but net earnings significantly declined due to substantial R&D investments and impairment charges.

AbbVie reports robust revenue growth driven by new immunology and neuroscience drugs, offsetting Humira's biosimilar impact, despite a dip in net earnings due to contingent consideration adjustments.

AbbVie's Q1 2025 results showcase revenue growth driven by key products like Skyrizi and Rinvoq, alongside strategic acquisitions and pipeline advancements.

AbbVie's Q3 2024 results show a 3% increase in net revenue and diluted earnings per share of $0.88, impacted by recent acquisitions and ongoing market dynamics.

AbbVie's 2024 Form 10-K reveals a 4% revenue increase driven by Skyrizi and Rinvoq, offsetting Humira's biosimilar impact, alongside strategic acquisitions and pipeline advancements.

AbbVie's 10-K filing outlines the company's registered securities, capital stock structure, and various corporate governance provisions.

AbbVie Inc. director Susan E. Quaggin reported transactions involving stock equivalent units, reflecting compensation and dividend reinvestment.

AbbVie Inc. director Thomas J. Falk has reported transactions involving restricted stock units and common stock.

AbbVie Inc. director Frederick H. Waddell acquired restricted stock units under the company's incentive program.

AbbVie Inc. director Rebecca B. Roberts acquired 1,118 restricted stock units under the company's incentive program.

AbbVie Inc. director Edward J. Rapp has reported transactions involving restricted stock units and common stock, reflecting changes in beneficial ownership.

AbbVie Inc. director Susan E. Quaggin reported the acquisition of 1,118 restricted stock units under the company's incentive stock program.

AbbVie's latest proxy statement highlights robust 2025 financial performance, key governance proposals including eliminating supermajority voting, and director elections for the upcoming 2026 Annual Meeting.

AbbVie Inc. announces its 2025 Annual Meeting of Stockholders to be held on May 9, 2025, featuring key proposals including the election of directors, ratification of the company's accounting firm, executive compensation, and voting amendments.

AbbVie's 2025 proxy statement outlines key governance changes, including a CEO transition and a proposal to eliminate supermajority voting, alongside details on executive compensation and director nominees.

AbbVie Inc. has scheduled its Annual Meeting for May 3, 2024, and is soliciting shareholder votes on key proposals, including the election of directors, ratification of auditors, executive compensation, and amendments to corporate governance.

AbbVie's 2024 proxy statement details key proposals for the annual meeting, including director elections, auditor ratification, executive compensation, and governance changes.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in AbbVie Inc. following an internal corporate realignment.

The Vanguard Group has filed an amended Schedule 13G, reporting a 10.03% beneficial ownership stake in AbbVie Inc. as of June 30, 2025.

AbbVie Inc. has disclosed a significant 9.0% beneficial ownership stake in Xilio Therapeutics, Inc., acquiring over 4.3 million shares of common stock.